Form 4: Director William Waddill Executes PTGX Stock Option Plan
Statement of Changes in Beneficial Ownership
Director William D. Waddill exercised options and sold 9,000 shares of Protagonist Therapeutics, Inc. under a 10b5-1 plan.
Summary
- Director William D. Waddill exercised 9,000 stock options at a strike price of $11.80 per share.
- Following the exercise, the director sold the 9,000 shares at an average price of $99.64 per share.
- The transactions were executed on May 29, 2026, pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2026.
- The director's direct beneficial ownership of common stock stands at 7,825 shares following these transactions.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event; it is a routine, pre-planned divestment by a director that does not signal a change in company fundamentals.
Positives
- The transaction was pre-planned under a Rule 10b5-1 plan, indicating a systematic approach to liquidity rather than reactive selling.
Negatives
- The director reduced their direct beneficial ownership stake in the company.
Risks
- Insider selling can sometimes be perceived negatively by retail investors, though this was conducted via a pre-arranged plan.
Future Outlook
No specific forward-looking guidance regarding company operations was provided in this filing.
Industry Context
StockSavvy.ai notes that routine insider selling via 10b5-1 plans is common in the biotechnology sector, particularly when stock prices have appreciated significantly, allowing directors to realize gains from long-held equity compensation.
Comparison to Industry Standards
- The use of 10b5-1 plans is the industry standard for corporate insiders to sell shares while avoiding potential accusations of insider trading.
- The transaction size is relatively small compared to the total market capitalization of Protagonist Therapeutics.
Stakeholder Impact
- Minimal impact on shareholders as the sale was executed through a pre-arranged 10b5-1 plan.
Next Steps
- No further actions or milestones were disclosed in this filing.
Key Dates
| Date | Description |
|---|---|
| 02/27/2026 | Date the 10b5-1 trading plan was adopted. |
| 05/29/2026 | Date of the option exercise and subsequent share sale. |
| 06/01/2026 | Date the Form 4 was signed and filed. |
| 06/06/2029 | Expiration date of the original stock options. |
Keywords
Protagonist Therapeutics, PTGX, Insider Trading, Form 4, Stock Options, Biotech
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.